Low seroprevalence of sandfly fever Sicilian virus antibodies in humans, Marseille, FranceArchived
A seroprevalence study was carried out in the region of Marseille (south-eastern France) to address the public health importance of sandfly fever Sicilian virus (SFSV) and SFSV-like viruses, as recently recognized vectors of those viruses are present in this area.
Bichaud L1, Piarroux RP1, Izri A2, Ninove L1, Mary C3, De Lamballerie X1, Charrel RN1.1 UMR190 (Université de la Méditerranée Aix-Marseille 2 – IRD), Marseille2 Laboratoire de Parasitologie-Mycologie, AP-HP Avicenne, Bobigny3 Laboratoire de Parasitologie-Mycologie, AP-HM Timone, Marseille, FranceClinical microbiology and infection 2011 Mar 14. doi: 10.1111/j.1469-0691.2011.03509.x. [Epub ahead of print]A seroprevalence study was carried out in the region of Marseille (south-eastern France) to address the public health importance of sandfly fever Sicilian virus (SFSV) and SFSV-like viruses, as recently recognized vectors of those viruses are present in this area. The low seroprevalence rate observed in this study suggests that SFSV is not likely to be of major medical importance in the Marseille area.
VBORNET comment, 26/8/2010: Investigating the human exposure to sand fly fever Sicilian virus (SFSV) and antigenically-similar viruses in Marseille region (south-eastern France), Bichaud et al. found via immunofluroscence assay a seroprevalence rate of 1% (2/198) in residents of the area. Interestingly, this coincides with previous rates reported from France more than two decades ago. Also consistent is the observed rarity of Phlebotomus papatasi, the primary vector species for SFSV, in southern France, whereas P. perniciosus and P. ariasi occur at high levels. Another sand fly-borne virus belonging to the same family as SFSV, the Toscana virus (TOSV), is an important pathogen responsible for human aseptic meningitis and is frequently observed in France, the vectors being reported to be common in southern France. This illustrates how data on vector population reflect the presence and activity of associated infections in human population.
Extensively drug-resistant gonorrhoea: risk of further dissemination within and across Europe
1 Apr 2019 - ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.
Conclusions of the twentieth IHR Emergency Committee do not change the ECDC risk assessment for Europe concerning polio
11 Mar 2019 - Statement of the twentieth IHR Emergency Committee Regarding the International Spread of Poliovirus, 1 March 2019
WHO recommendations for influenza virus vaccine composition for the 2019–2020 northern hemisphere season
1 Mar 2019 - On 18–20 February 2019, the World Health Organization (WHO) agreed on the recommended composition of the quadrivalent influenza vaccine for the northern hemisphere 2019–2020 influenza season: an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A(H3N2) virus component to be announced on 21 March 2019, a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).